X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2596) 2596
Magazine Article (6) 6
Book Chapter (4) 4
Book Review (2) 2
Conference Proceeding (2) 2
Newsletter (2) 2
Reference (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2005) 2005
index medicus (1548) 1548
male (1368) 1368
female (1069) 1069
administration, inhalation (926) 926
adrenergic beta-2 receptor agonists - administration & dosage (875) 875
animals (747) 747
asthma - drug therapy (667) 667
middle aged (659) 659
pulmonary disease, chronic obstructive - drug therapy (657) 657
adult (634) 634
respiratory system (595) 595
asthma (560) 560
bronchodilator agents - administration & dosage (548) 548
treatment outcome (516) 516
adrenergic beta-2 receptor agonists - therapeutic use (510) 510
aged (503) 503
pharmacology & pharmacy (409) 409
drug therapy, combination (402) 402
adrenergic beta-2 receptor agonists - adverse effects (376) 376
pulmonary disease, chronic obstructive - physiopathology (348) 348
bronchodilator agents - therapeutic use (342) 342
copd (328) 328
adrenal cortex hormones - administration & dosage (307) 307
adrenergic beta-2 receptor agonists (305) 305
rats (300) 300
receptors, adrenergic, beta-2 - metabolism (293) 293
lung diseases, obstructive (291) 291
albuterol - administration & dosage (286) 286
drug therapy (284) 284
chronic obstructive pulmonary disease (277) 277
adrenergic beta-agonists - pharmacology (276) 276
dose-response relationship, drug (274) 274
time factors (272) 272
drug combinations (271) 271
obstructive pulmonary-disease (270) 270
double-blind method (251) 251
lung - drug effects (250) 250
adrenergic beta-2 receptor agonists - pharmacology (248) 248
bronchodilator agents - adverse effects (247) 247
adrenergic beta-agonists - administration & dosage (238) 238
adrenal cortex hormones - therapeutic use (236) 236
pulmonary disease, chronic obstructive - diagnosis (232) 232
receptors, adrenergic, beta-2 - genetics (231) 231
adolescent (227) 227
salmeterol (226) 226
muscarinic antagonists - administration & dosage (222) 222
lung - physiopathology (216) 216
child (212) 212
severity of illness index (208) 208
asthma - physiopathology (204) 204
formoterol (203) 203
mice (202) 202
forced expiratory volume (193) 193
research (190) 190
formoterol fumarate (187) 187
care and treatment (185) 185
adrenergic beta-agonists - therapeutic use (183) 183
corticosteroids (183) 183
young adult (180) 180
dosage and administration (175) 175
tiotropium (174) 174
double-blind (171) 171
albuterol - analogs & derivatives (163) 163
analysis (162) 162
cardiac & cardiovascular systems (162) 162
drug administration schedule (162) 162
efficacy (160) 160
safety (158) 158
glucocorticoids - administration & dosage (157) 157
diseases of the respiratory system (156) 156
exacerbations (156) 156
original research (155) 155
inhaled corticosteroids (154) 154
nebulizers and vaporizers (154) 154
receptors, adrenergic, beta-2 - drug effects (150) 150
salbutamol (148) 148
salmeterol xinafoate (148) 148
albuterol - therapeutic use (147) 147
anti-asthmatic agents - therapeutic use (146) 146
adrenergic beta-antagonists - pharmacology (142) 142
anti-asthmatic agents - administration & dosage (142) 142
pulmonary/respiratory (141) 141
randomized controlled trials as topic (141) 141
muscarinic antagonists - therapeutic use (139) 139
disease progression (137) 137
albuterol (136) 136
albuterol - pharmacology (136) 136
ethanolamines - administration & dosage (135) 135
cross-over studies (132) 132
respiratory tract diseases (132) 132
allergy (131) 131
forced expiratory volume - drug effects (131) 131
immunology (131) 131
risk factors (124) 124
international journal of chronic obstructive pulmonary disease (122) 122
medicine & public health (122) 122
aged, 80 and over (121) 121
muscarinic antagonists - adverse effects (120) 120
abridged index medicus (119) 119
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2524) 2524
German (27) 27
Japanese (26) 26
French (14) 14
Russian (10) 10
Danish (7) 7
Chinese (5) 5
Spanish (5) 5
Turkish (5) 5
Polish (3) 3
Hungarian (2) 2
Norwegian (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, ISSN 0012-1797, 05/2016, Volume 65, Issue 5, pp. 1410 - 1423
Beige adipocytes emerge postnatally within the white adipose tissue in response to certain environmental cues, such as chronic cold exposure. Because of its... 
THERMOGENESIS | WHITE FAT | ACTIVATED PROTEIN-KINASE | ENDOCRINOLOGY & METABOLISM | HYPOTHALAMIC AMPK | PPAR-GAMMA | BROWN ADIPOSE-TISSUE | CAPSICUM-ANNUUM | CH-19 SWEET | ENERGY-METABOLISM | TRANSCRIPTIONAL COMPLEX | Adipocytes, Beige - drug effects | Transcription Factors - chemistry | Capsaicin - therapeutic use | Adipogenesis - drug effects | Capsaicin - chemistry | Male | Hydrogenation | Anti-Obesity Agents - therapeutic use | Adrenergic beta-2 Receptor Agonists - pharmacology | Receptors, Adrenergic, beta-2 - chemistry | DNA-Binding Proteins - metabolism | Capsaicin - agonists | Adipocytes, Beige - pathology | Adrenergic beta-2 Receptor Agonists - therapeutic use | Anti-Obesity Agents - antagonists & inhibitors | Adrenergic beta-2 Receptor Antagonists - pharmacology | Anti-Obesity Agents - agonists | Cold Temperature | Obesity - chemically induced | Receptors, Adrenergic, beta-2 - genetics | Mice, Inbred C57BL | Cells, Cultured | Acclimatization | Adrenergic beta-2 Receptor Antagonists - toxicity | Capsaicin - analogs & derivatives | Mice, Transgenic | Adipocytes, Beige - cytology | Random Allocation | Transcription Factors - genetics | DNA-Binding Proteins - genetics | DNA-Binding Proteins - chemistry | Receptors, Adrenergic, beta-2 - metabolism | Obesity - metabolism | Obesity - pathology | Gene Expression Regulation - drug effects | Transcription Factors - metabolism | Animals | Signal Transduction - drug effects | Oxygen Consumption - drug effects | Obesity - prevention & control | Protein Stability - drug effects | Capsaicin - antagonists & inhibitors | Dietary Supplements | Energy Metabolism - drug effects | Adipocytes, Beige - physiology | Weight reducing preparations | Obesity | Complications and side effects | Fat cells | Dosage and administration | Research | Beta adrenoceptors | Pharmacology and Therapeutics
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2011, Volume 337, Issue 3, pp. 600 - 609
beta(2)-Adrenoceptor (beta(2)-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease... 
BETA-ADRENOCEPTOR AGONISTS | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | ASTHMA | PHARMACOLOGY & PHARMACY | BETA-2-ADRENOCEPTOR AGONIST | SELECTIVITY | BURDEN | BETA-ADRENERGIC RECEPTOR | SALMETEROL | COPD | Adrenergic beta-2 Receptor Agonists - pharmacokinetics | Ethanolamines - pharmacology | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Albuterol - pharmacology | Humans | Half-Life | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Adrenergic beta-2 Receptor Agonists - pharmacology | Bronchodilator Agents - chemistry | Ethanolamines - pharmacokinetics | Benzoxazines - pharmacokinetics | Albuterol - administration & dosage | Binding Sites | Benzoxazines - chemistry | Cricetinae | Salmeterol Xinafoate | Benzoxazines - administration & dosage | Adrenergic beta-2 Receptor Agonists - chemistry | Administration, Inhalation | Albuterol - analogs & derivatives | Albuterol - pharmacokinetics | Bronchodilator Agents - pharmacology | Receptors, Adrenergic, beta-1 - metabolism | Ethanolamines - chemistry | Asthma - drug therapy | Receptors, Adrenergic, beta-2 - metabolism | Animals | Bronchodilator Agents - pharmacokinetics | Benzoxazines - pharmacology | Adrenergic beta-2 Receptor Agonists - administration & dosage | Albuterol - chemistry | Mice | Mice, Inbred BALB C | Lipid Bilayers - metabolism | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Thorax, ISSN 0040-6376, 02/2014, Volume 69, Issue 2, pp. 130 - 136
Background In mild asthma exercise-induced bronchoconstriction (EIB) is usually treated with inhaled short-acting β2 agonists (SABAs) on demand... 
BECLOMETHASONE | MAINTENANCE | RESPIRATORY SYSTEM | TOLERANCE | RELIEVER THERAPY | BUDESONIDE | METHACHOLINE | INDUCED BRONCHOSPASM | BETA-AGONISTS | CHILDREN | SALMETEROL | Bronchodilator Agents - therapeutic use | Terbutaline - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Terbutaline - therapeutic use | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Asthma, Exercise-Induced - physiopathology | Humans | Male | Ethanolamines - administration & dosage | Vital Capacity - drug effects | Young Adult | Terbutaline - administration & dosage | Adrenergic beta-2 Receptor Agonists - adverse effects | Exercise Test - methods | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Asthma, Exercise-Induced - prevention & control | Budesonide - adverse effects | Budesonide - therapeutic use | Adolescent | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Budesonide - administration & dosage | Budesonide | Formoterol | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Asthma | Exercise | Fitness equipment | Steroids | 1506 | Clinical Medicine | Lungmedicin och allergi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Respiratory Medicine and Allergy
Journal Article
Biological & pharmaceutical bulletin, 2018, Volume 41, Issue 2, p. 272
... -adrenoceptor agonist salbutamol. The vasodilator effect of BMS-191011, a large... 
GTP-Binding Protein alpha Subunits, Gs - metabolism | Retina - drug effects | Oxadiazoles - administration & dosage | GTP-Binding Protein alpha Subunits, Gs - chemistry | Retina - metabolism | Injections, Intravenous | Pyruvaldehyde - administration & dosage | Intravitreal Injections | Albuterol - pharmacology | Male | Adrenergic beta-2 Receptor Agonists - pharmacology | Receptors, Adrenergic, beta-2 - chemistry | Dose-Response Relationship, Drug | Pyruvaldehyde - metabolism | Oxadiazoles - pharmacology | Albuterol - administration & dosage | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits - agonists | Vasodilator Agents - pharmacology | Retinal Vessels - metabolism | Colforsin - pharmacology | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits - antagonists & inhibitors | Colforsin - administration & dosage | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits - metabolism | GTP-Binding Protein alpha Subunits, Gs - antagonists & inhibitors | Retinal Vessels - drug effects | Calcium Channel Blockers - pharmacology | Arterioles - drug effects | Rats, Sprague-Dawley | Receptors, Adrenergic, beta-2 - metabolism | Peptides - pharmacology | Calcium Channel Agonists - administration & dosage | Animals | Arterioles - metabolism | Adrenergic beta-2 Receptor Antagonists - administration & dosage | Adrenergic beta-2 Receptor Antagonists - metabolism | Adrenergic beta-2 Receptor Agonists - administration & dosage | Calcium Channel Agonists - pharmacology | Vasodilation - drug effects | Vasodilator Agents - administration & dosage
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2013, Volume 169, Issue 6, pp. 1279 - 1289
Background and Purpose Retigabine is a recently approved antiepileptic agent which activates Kv7.2–7.5 potassium channels. It is emerging that these channels... 
β‐adrenoceptors | retigabine | conscious rats | KCNQ | Kv7 | hypertension | haemodynamic responses | β-adrenoceptors | KCNQ POTASSIUM CHANNELS | ANTICONVULSANT RETIGABINE | SAFETY | INVOLVEMENT | ANGIOTENSIN-II | EZOGABINE RETIGABINE | ARTERIES | VASOPRESSIN | PHARMACOLOGY & PHARMACY | adrenoceptors | EXPRESSION | MODULATION | Phenylenediamines - adverse effects | Antihypertensive Agents - pharmacology | Arrhythmias, Cardiac - chemically induced | Cricetulus | Phenylenediamines - therapeutic use | Humans | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Carbamates - administration & dosage | Phenylenediamines - administration & dosage | Adrenergic beta-2 Receptor Agonists - pharmacology | KCNQ2 Potassium Channel - agonists | Receptors, Adrenergic, beta-2 - chemistry | Dose-Response Relationship, Drug | KCNQ2 Potassium Channel - metabolism | Adrenergic beta-2 Receptor Agonists - adverse effects | Membrane Transport Modulators - pharmacology | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adrenergic beta-Agonists - therapeutic use | CHO Cells | Carbamates - pharmacology | Recombinant Proteins - metabolism | Receptors, Adrenergic, beta-2 - genetics | KCNQ Potassium Channels - agonists | Adrenergic beta-Agonists - pharmacology | Rats | Recombinant Proteins - chemistry | Membrane Transport Modulators - administration & dosage | Random Allocation | Antihypertensive Agents - therapeutic use | Rats, Sprague-Dawley | Receptors, Adrenergic, beta-2 - metabolism | Antihypertensive Agents - adverse effects | Animals | KCNQ Potassium Channels - metabolism | Membrane Transport Modulators - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Carbamates - adverse effects | Phenylenediamines - pharmacology | Coronary Circulation - drug effects | Vasodilation - drug effects | Carbamates - therapeutic use | Membrane Transport Modulators - adverse effects | Hypertension | Propranolol hydrochloride | Anticonvulsants | Vasopressin | Angiotensin | Rodents | Research Papers
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 09/2011, Volume 184, Issue 5, pp. 561 - 568
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
.... The LANTERN study evaluated the effect of the long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article